羚锐制药(600285) - 2021 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 26.19% to CNY 96,577,254.45 year-on-year[18] - Operating income grew by 20.01% to CNY 589,387,940.52 compared to the same period last year[18] - The company reported a net profit of CNY 90,288,128.77 after deducting non-recurring gains and losses, an increase of 21.61% year-on-year[18] - The company reported a net profit of ¥1,244,309,339.19 for Q1 2021, compared to ¥1,121,856,244.08 in Q1 2020, representing an increase of approximately 10.9%[50] - Net profit for the period was ¥96.58 million, representing a 26.7% increase from ¥76.22 million in the same period last year[54] - The total profit for the period was ¥112.96 million, up 25.4% from ¥90.18 million in the previous year[54] Earnings and Shareholder Metrics - Basic earnings per share increased by 25.93% to CNY 0.170 compared to the same period last year[21] - The company reported a basic earnings per share of ¥0.170, compared to ¥0.135 in the previous year[56] - The weighted average return on equity rose by 0.69 percentage points to 4.09%[18] - The total number of shareholders reached 41,377 by the end of the reporting period[27] - The largest shareholder, Henan Lingrui Group Co., Ltd., holds 21.45% of the shares, with 121,817,898 shares pledged[27] Assets and Liabilities - Total assets increased by 9.03% to CNY 3,770,058,019.82 compared to the end of the previous year[18] - The company’s total equity attributable to shareholders increased by 4.75% to CNY 2,422,675,006.05 compared to the end of the previous year[18] - Total liabilities increased to ¥1,337,940,855.27 from ¥1,135,601,711.01, representing a growth of approximately 17.8% year-over-year[43] - Total current liabilities increased to ¥1,111,490,597.08 from ¥932,220,660.31, reflecting a growth of approximately 19.3%[50] - Total current assets as of December 31, 2020, amounted to CNY 1,916,540,670.70, with a slight decrease of CNY 503,596.41 on January 1, 2021[73] Cash Flow - Net cash flow from operating activities increased by 61.63% to CNY 225,388,370.58 year-on-year[18] - Cash and cash equivalents increased to ¥1,059,501,093.79, up 44.68% from ¥732,316,860.77 due to cash generated from operating activities[30] - Operating cash inflow totaled ¥661,161,184.13, compared to ¥531,592,788.82 in the previous year, reflecting a growth of approximately 24.4%[65] - Cash inflow from financing activities was ¥110,000,000.00, an increase from ¥100,000,000.00 in the previous year[67] - Cash flow from investment activities showed a net outflow of ¥37,284,058.87, a recovery from a net outflow of ¥170,885,562.80 in the previous year[65] Operational Metrics - Total operating revenue reached ¥589.39 million, an increase of 20% compared to ¥491.10 million in the previous period[54] - Total operating costs amounted to ¥479.66 million, up 20.6% from ¥397.62 million year-over-year[54] - Research and development expenses increased to ¥11.58 million, up 20% from ¥9.65 million year-over-year[54] - The company achieved an operating profit of ¥112.91 million, an increase of 25.4% from ¥90.10 million year-over-year[54] Other Financial Metrics - Other income increased by 178.95% to ¥7,258,181.08 from ¥2,601,922.81, mainly due to a higher amount of government subsidies received[30] - Deferred income tax liabilities increased by 43.29% to ¥30,215,774.07 from ¥21,086,851.26, primarily due to changes in the fair value of other equity instruments[30] - Total comprehensive income reached ¥159,901,101.36, a significant increase from ¥70,739,584.14[62] - Other comprehensive income after tax was ¥37.76 million, a significant recovery from a loss of ¥4.61 million in the prior period[56] Share Repurchase and Future Plans - The company repurchased a total of 2,899,300 shares, accounting for 0.51% of the total share capital, with a total payment of ¥25,215,362.14[34] - The company plans to repurchase shares with a budget between ¥100 million and ¥200 million at a price not exceeding ¥12 per share for employee incentive plans[32] - The company plans to continue expanding its market presence and investing in new product development to sustain growth[62]